The global lipoprotein market represents a critical segment within cardiovascular diagnostics and therapeutic development, driven by increasing cardiovascular disease prevalence, aging populations, and advancing precision medicine approaches. Lipoproteins—complex particles composed of lipids and proteins that transport fats through the bloodstream—play essential roles in cardiovascular health assessment, with high-density lipoprotein (HDL), low-density lipoprotein (LDL), and lipoprotein(a) [Lp(a)] serving as key biomarkers for atherosclerosis risk stratification. According to comprehensive market analysis, the global high-density lipoprotein cholesterol market reached approximately $120 billion in 2024, projected to exceed $130 billion in 2025​ and expand to $220 billion by 2030​ with a compound annual growth rate (CAGR) of 8.5%​ . The low-density lipoprotein testing market…